©NIJRMS
Publications 2025

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES (NIJRMS)

Volume 7 Issue 1 Page 81-86, 2026

https://doi.org/10.59298/NIJRMS/2026/7.1.8186

Nanotechnology in the Management of Obesity and Diabetes: A Convergent Frontier in Metabolic Disease Therapy

Maina Mwaura F.

School of Natural and Applied Sciences Kampala International University Uganda

ABSTRACT

Obesity and diabetes mellitus (DM) are interrelated global health crises, jointly termed *diabesity*, that arise from complex metabolic, genetic, and behavioral factors. Both conditions promote insulin resistance, oxidative stress, and systemic inflammation, predisposing patients to cardiovascular and hepatic comorbidities. Conventional pharmacotherapy is hampered by low bioavailability, off-target toxicity, and poor compliance, creating an urgent need for innovative modalities. Nanotechnology offers transformative potential by improving drug solubility, stability, and targeted delivery while enabling precise glucose monitoring and metabolic regulation. Nanoscale carriers such as liposomes, dendrimers, solid lipid nanoparticles (SLNs), and polymeric nanostructures facilitate controlled drug release, enhance intestinal permeability, and enable tissue-specific accumulation in adipose or pancreatic tissues. Metallic nanoparticles and quantum dots have also advanced biosensing applications, allowing real-time detection of glucose and insulin biomarkers. Moreover, nanotheranostic systems integrate diagnostic and therapeutic capabilities, aligning with personalized medicine paradigms. Despite promising preclinical data, translational challenges, including immunogenicity, scalability, and regulatory uncertainty, impede clinical adoption. This review outlines recent advances in nano-enabled antidiabetic and anti-obesity therapies, highlighting mechanistic insights, nanotoxicological considerations, and the roadmap toward safe clinical translation. Nanotechnology thus emerges as a convergent frontier for addressing diabesity through precision, biocompatibility, and multifunctional design.

Keywords: Nanotechnology; Obesity; Diabetes Mellitus; Drug Delivery; Metabolic Therapy

INTRODUCTION

Obesity and diabetes mellitus (particularly type 2 diabetes, T2DM) represent synergistic pandemics with shared pathophysiology centered on energy imbalance, adipocyte dysfunction, and insulin resistance[1–4]. Both conditions stem from sedentary lifestyles and high-calorie diets that induce lipid accumulation in adipose and ectopic tissues. Adipocyte hypertrophy triggers chronic low-grade inflammation characterized by TNF-α, IL-6, and MCP-1 secretion, disrupting insulin receptor signaling and promoting hepatic steatosis[5–7]. The resulting *diabesity* syndrome underlies cardiovascular disease, neuropathy, and non-alcoholic fatty liver disease, collectively burdening global healthcare systems.

Conventional management, dietary control, exercise, oral hypoglycemics, and insulin offer only partial remission. Most antidiabetic agents (metformin, sulfonylureas, GLP-1 analogs) suffer from low bioavailability or systemic side effects[8–11]. Likewise, anti-obesity drugs (orlistat, liraglutide) often cause gastrointestinal intolerance or rebound weight gain. Hence, novel delivery systems that enhance drug stability, reduce dosing frequency, and ensure tissue selectivity are urgently required[12, 13].

Nanotechnology, manipulating materials at the 1–100 nm scale, enables molecular precision in drug design[14–16]. Nanocarriers can protect labile molecules from enzymatic degradation, cross biological membranes, and release cargo in response to pH, redox, or enzymatic stimuli. In metabolic disease therapy, nanoplatforms improve pharmacokinetics and site-specific delivery of insulin, metformin, or lipase inhibitors. For instance, polymeric nanoparticles (NPs) encapsulating metformin enhances intestinal absorption, while chitosan-coated

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

insulin nanocapsules survive gastric acidity, allowing oral administration. Such systems minimize hypoglycemic risk and patient discomfort associated with injections[17–19].

Beyond therapeutics, nanotechnology revolutionizes diagnostics. Glucose nanosensors based on graphene, gold, or carbon nanotubes detect minute fluctuations in blood glucose with high sensitivity, enabling continuous glucose monitoring (CGM). Integration with wearable electronics and wireless data transfer supports real-time feedback and personalized insulin titration[20, 21]. Emerging nanomedicine concepts extend to theranostics hybrid platforms combining therapeutic delivery and diagnostic imaging[22–25]. For diabesity, this translates to nanoparticles simultaneously releasing insulin while tracking glucose levels or inflammation markers through optical or magnetic signals. Moreover, nanostructures can modulate metabolic pathways: iron-oxide NPs stimulate brown adipose thermogenesis, while cerium-oxide NPs reduce oxidative stress in pancreatic β-cells.

Despite the promise, challenges persist. Nanoparticle biocompatibility, long-term biodistribution, and potential accumulation in the liver or spleen raise safety concerns. Regulatory frameworks lag behind technological advances, complicating clinical approval. Nonetheless, as interdisciplinary collaborations expand, nanotechnology is poised to transform diabesity management from symptomatic control to mechanistic precision, heralding a new era of metabolic medicine.

2. Nanocarrier Systems in Antidiabetic Therapy

Nanocarrier systems have reshaped antidiabetic pharmacology by optimizing drug delivery and enhancing therapeutic index. Polymeric nanoparticles (e.g., PLGA, chitosan, PEGylated systems) offer controlled release and protection of bioactive molecules[26–28]. Encapsulation of insulin in chitosan-PEG nanoparticles increases mucosal adhesion and allows absorption through intestinal Peyer's patches, effectively mimicking parenteral delivery. Similarly, metformin-loaded PLGA nanoparticles prolong systemic exposure, improving glycemic control with lower doses[26, 27, 29].

Liposomes like spherical phospholipid vesicles, improve the solubility of hydrophilic and hydrophobic drugs. Insulin liposomes coated with bile salts exhibit enhanced intestinal permeability and enzymatic resistance, a key milestone toward oral insulin. Dendrimers, with their branched architecture and tunable surface groups, facilitate covalent attachment of glucose-responsive moieties or cell-penetrating ligands[30–33]. PAMAM dendrimer conjugates have been shown to target pancreatic β-cells selectively, enhancing insulin secretion without systemic toxicity.

Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) provide high drug loading and stability for lipophilic antidiabetic compounds such as pioglitazone and glibenclamide[3, 34]. Their lipid matrix offers biocompatibility and sustained release, maintaining steady plasma concentrations. Hybrid nanocarriers combining polymeric and lipid features further improve pharmacodynamics and minimize burst release. Nanocarriers can also co-deliver synergistic drugs[8, 9, 12]. Dual-loaded systems containing insulin and GLP-1 analogs achieve glucose-responsive co-release, addressing multiple diabetic targets simultaneously. Moreover, surface modification with lectins, antibodies, or peptides enhances intestinal and hepatic targeting, reducing off-target deposition[35].

Importantly, these nanoformulations reduce dosing frequency and improve patient adherence. However, large-scale production remains difficult due to stability and reproducibility challenges. The translation of laboratory prototypes into clinical products demands harmonized quality-by-design protocols and detailed toxicity profiling. Nonetheless, nanocarrier-mediated antidiabetic therapy marks a paradigm shift toward precision glycemic control.

3. Nano-Based Strategies for Obesity Management

Nanotechnology also enables novel anti-obesity strategies targeting adipogenesis, lipid absorption, and energy expenditure[36]. Nanoemulsions carrying lipase inhibitors such as orlistat enhance intestinal localization and reduce systemic side effects. Encapsulation improves drug solubility, enabling lower doses with equivalent efficacy. Similarly, micellar systems transporting appetite-suppressing peptides or cannabinoid receptor antagonists prolong their stability and central nervous system penetration[37].

Thermogenic nanoplatforms that activate brown adipose tissue (BAT) or induce "browning" of white adipocytes are gaining traction[38]. For instance, gold or iron-oxide nanoparticles functionalized with thermogenic ligands increase mitochondrial uncoupling protein 1 (UCP1) expression, boosting caloric expenditure. Photothermal nanoparticles responsive to near-infrared light can locally stimulate lipolysis, offering non-invasive fat-reduction potential[38]. Nanocarriers also assist in modulating gut microbiota, an emerging determinant of obesity. Delivery of probiotics, polyphenols, or short-chain fatty acid precursors through protective nanocapsules ensures viability through gastric passage and controlled release in the colon, thereby restoring microbial balance and improving metabolic signaling via GLP-1 and PYY pathways[38].

Another avenue involves gene-silencing nanotherapies. siRNA-loaded lipidoid nanoparticles targeting PPAR-γ or FABP4 downregulate adipogenesis and lipid storage in adipose tissue. These gene-specific approaches exemplify nanomedicine's capacity for molecular precision[39].

Despite encouraging preclinical outcomes, obesity nanotherapy faces translational hurdles, particularly in long-term safety and off-target thermogenic activation[39]. Nevertheless, the capacity of nanosystems to deliver

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041
multifunctional, tissue-targeted interventions positions them as key tools for next-generation obesity therapeutics integrated with metabolic disease management.

4. Nanodiagnostics and Biosensors in Glucose Monitoring

Continuous glucose monitoring (CGM) remains central to diabetes management [40]. Nanotechnology enhances biosensor sensitivity, miniaturization, and biocompatibility[41]. Enzyme-based nanosensors utilize glucose oxidase immobilized on conductive nanomaterials such as gold nanoparticles, carbon nanotubes, or graphene sheets to generate electrochemical signals proportional to glucose concentration. These systems detect micromolar glucose levels with rapid response times[41].

Graphene-oxide platforms exhibit a large surface area and excellent electron mobility, enabling wearable, non-invasive sensors integrated into smartwatches or skin patches[42]. Quantum-dot-based optical sensors emit fluorescence modulated by glucose concentration, facilitating continuous readouts without blood sampling. Magnetic nanoparticles have been applied in magneto-elastic biosensors, translating magnetic resonance shifts into digital glucose data[42]. Beyond glucose, nanodiagnostics target insulin, glycated hemoglobin, and inflammatory biomarkers. Dual-analyte nanosensors combine glucose oxidase with catalase to mitigate oxygen dependence, improving accuracy under variable physiological conditions. Integration with wireless microelectronics supports real-time data transmission to smartphones and cloud-based monitoring platforms, enabling personalized therapy algorithms[43].

Recent efforts explore *theranostic nanosensors*, nanostructures that not only detect glucose but also trigger insulin release upon hyperglycemia. For example, phenylboronic-acid-functionalized nanoparticles swell in response to elevated glucose, releasing encapsulated insulin autonomously. Such feedback-controlled nanosystems emulate pancreatic β-cell physiology[43]. Challenges include sensor fouling, immune response at implantation sites, and long-term stability of nanomaterials in biological fluids. Nevertheless, nanodiagnostics offer transformative potential for closed-loop diabetes management, merging detection, decision, and delivery within a unified nanoscale framework.

5. Mechanistic Insights: Cellular and Molecular Interactions

The efficacy of nanomedicine in metabolic disorders depends on its cellular and molecular interactions. Nanoparticles enter cells mainly via endocytosis, clathrin-mediated, caveolae-mediated, or macropinocytic routes depending on size, charge, and surface chemistry[44]. Once internalized, they interact with subcellular organelles, influencing metabolic signaling.

In pancreatic β-cells, certain nanoparticles (e.g., cerium oxide or selenium NPs) scavenge reactive oxygen species (ROS), protecting cells from oxidative stress-induced apoptosis and preserving insulin secretion[44, 45]. In adipocytes, polymeric nanoparticles delivering AMPK activators or PPAR-α agonists enhance fatty acid oxidation and thermogenesis, reversing insulin resistance. Similarly, hepatic delivery of siRNA via lipid nanoparticles modulates gluconeogenic genes such as G6Pase and PEPCK, improving glucose homeostasis.

Surface modifications dictate tissue tropism[45]. For instance, mannose-decorated nanoparticles target hepatocytes through the asialoglycoprotein receptor, while RGD-peptide ligands enhance endothelial uptake[46]. PEGylation reduces opsonization, extending circulation time and minimizing immune clearance. At the molecular level, nanoparticle interaction with cellular membranes can alter ion channels and mitochondrial potential, occasionally triggering autophagy or apoptosis if concentration thresholds are exceeded. Understanding these dose-dependent effects is vital to optimizing the therapeutic index[46].

Nanoparticle shape also influences function: rods exhibit higher cellular uptake than spheres, while smaller (< 50 nm) particles penetrate deeper into adipose and hepatic tissue. Hence, nanosystem design must integrate physicochemical parameters with target-specific biology to achieve safe and effective metabolic modulation.

6. Safety, Toxicity, and Regulatory Challenges

Despite therapeutic promise, nanotechnology faces scrutiny over safety and regulation. Nanoparticles may induce cytotoxicity through oxidative stress, DNA damage, or immune activation, depending on composition and surface reactivity[47]. Metallic nanoparticles, such as silver or titanium dioxide, can generate ROS and disrupt mitochondrial function, necessitating surface passivation or biopolymer coating to mitigate toxicity[47].

Biodegradable polymers (PLGA, chitosan) generally exhibit favorable safety profiles, but long-term accumulation in the liver, spleen, or kidneys remains a concern. Pharmacokinetic profiling and chronic toxicity studies are mandatory for clinical translation. Moreover, the protein corona formed when nanoparticles contact plasma can alter biodistribution and immune recognition, complicating predictability[48].

Regulatory pathways for nanomedicines are still evolving. Agencies such as the FDA and EMA lack standardized guidelines for nanoparticle characterization, batch reproducibility, and safety thresholds[49]. Each nanocarrier must be evaluated for particle size distribution, zeta potential, dissolution kinetics, and in vivo metabolism. Ethical considerations include potential environmental accumulation and inequitable access to costly nano-therapeutics[49].

Toxicological evaluation increasingly relies on high-throughput in vitro assays and computational modeling to predict nano-bio interactions. Still, translating preclinical safety data to human outcomes is challenging due to

interspecies variability[49]. Therefore, multidisciplinary collaboration between chemists, toxicologists, and clinicians is essential to establish evidence-based regulatory frameworks ensuring both innovation and patient safety.

7. Future Perspectives

The convergence of nanotechnology with endocrinology heralds a new era in metabolic medicine. Future research focuses on *smart nanotheranostics* systems capable of sensing metabolic cues and releasing drugs accordingly, thereby achieving autonomous homeostatic control. Integration with artificial intelligence (AI) will accelerate nanocarrier design through predictive modeling of pharmacokinetics, toxicity, and target binding.

Advances in biodegradable and stimuli-responsive materials promise improved safety and clearance. For example, pH- or glucose-responsive hydrogels encapsulating insulin may enable fully closed-loop delivery systems. Nano-enabled tissue engineering could regenerate pancreatic islets using nanofibrous scaffolds, releasing growth factors in situ.

Personalized nanomedicine guided by genomic, metabolomic, and microbiome data will tailor formulations to individual metabolic profiles. Furthermore, hybrid nanocarriers combining synthetic polymers with natural compounds (curcumin, resveratrol) may synergize metabolic and antioxidant effects.

Collaboration between academia, industry, and regulatory agencies is critical to transition from bench to bedside. Transparent safety databases, standardized testing, and cost-effective, scalable synthesis will determine clinical viability.

CONCLUSION

In conclusion, nanotechnology provides a versatile and integrative platform to address the dual burden of obesity and diabetes. By bridging therapy and diagnostics, enhancing drug efficacy, and enabling personalized control of metabolism, nanomedicine stands as a cornerstone of future diabesity management, transforming reactive treatment into proactive, precision-guided care.

REFERENCES

1. Allocca, S., Monda, A., Messina, A., Casillo, M., Sapuppo, W., Monda, V., Polito, R., Di Maio, G., Monda, M., La Marra, M.: Endocrine and Metabolic Mechanisms Linking Obesity to Type 2 Diabetes: Implications for Targeted Therapy. Healthcare. 13, 1437 (2025). https://doi.org/10.3390/healthcare13121437
2. Nnolum-Orji, N.F., Kumar, P., Ngema, L.M., Choonara, Y.E.: Adipose tissue NLRP3 inflammasome: a therapeutic target in obesity and type 2 diabetes mellitus. Drug Discov. Today. 30, 104456 (2025). https://doi.org/10.1016/j.drudis.2025.104456
3. Bakshi, V., Fathima, B.: Solid Lipid Nanoparticles in Metabolic Disorders: A Novel Strategy for Targeted Delivery in Diabetes and Obesity. J. Bio-X Res. 8, 0066 (2025). https://doi.org/10.34133/jbioxresearch.0066
4. Ferguson, R.D., Gallagher, E.J., Scheinman, E.J., Damouni, R., LeRoith, D.: The epidemiology and molecular mechanisms linking obesity, diabetes, and cancer. Vitam. Horm. 93, 51–98 (2013). https://doi.org/10.1016/B978-0-12-416673-8.00010-1
5. Cavaliere, G., Cimmino, F., Trinchese, G., Catapano, A., Petrella, L., D'Angelo, M., Lucchin, L., Mollica, M.P.: From Obesity-Induced Low-Grade Inflammation to Lipotoxicity and Mitochondrial Dysfunction: Altered Multi-Crosstalk between Adipose Tissue and Metabolically Active Organs. Antioxidants. 12, 1172 (2023). https://doi.org/10.3390/antiox12061172
6. Uti, D.E., Atangwho, I.J., Omang, W.A., Alum, E.U., Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obes. Med. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
7. Izah, S.C., Betiang, P.A., Paul-Chima Ugwu, O., Ainebyoona, C., Uti, D.E., Echegu, D.A.: The Ketogenic Diet in Obesity Management: Friend or Foe? Cell Biochem. Biophys. (2025). https://doi.org/10.1007/s12013-025-01878-0
8. Chai, S., Niu, Y., Liu, F., Wu, S., Yang, Z., Sun, F.: Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review. J. Diabetes Res. 2024, 8145388 (2024). https://doi.org/10.1155/2024/8145388
9. Min, S.H.: Mechanisms of Glucagon Receptor Agonism and GLP-1/Glucagon/GIP Receptor Triple Agonism for Treatment of Diabetes and Obesity. J. Korean Diabetes. 25, 82–88 (2024). https://doi.org/10.4093/jkd.2024.25.2.82
10. Poudwal, S., Misra, A., Shende, P.: Role of lipid nanocarriers for enhancing oral absorption and bioavailability of insulin and GLP-1 receptor agonists. J. Drug Target. 29, 834–847 (2021). https://doi.org/10.1080/1061186X.2021.1894434
11. Tasyurek, M.H., Altunbas, H.A., Canatan, H., Griffith, T.S., Sanlioglu, S.: GLP-1-mediated gene therapy approaches for diabetes treatment. Expert Rev. Mol. Med. 16, e7 (2014). https://doi.org/10.1017/erm.2014.7

12. Reiss, A.B., Gulkarov, S., Lau, R., Klek, S.P., Srivastava, A., Renna, H.A., De Leon, J.: Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss. Biomolecules. 15, 408 (2025). https://doi.org/10.3390/biom15030408
13. Zeng, J., Tang, X., Qin, D., Yu, L., Zhou, X., Feng, C., Mi, J., Pan, H., Wu, J., Huang, B., Wu, A.: Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases. J. Nanobiotechnology. 23, 682 (2025). https://doi.org/10.1186/s12951-025-03677-4
14. Anjum, S., Ishaque, S., Fatima, H., Farooq, W., Hano, C., Abbasi, B.H., Anjum, I.: Emerging Applications of Nanotechnology in Healthcare Systems: Grand Challenges and Perspectives. Pharmaceuticals. 14, 707 (2021). https://doi.org/10.3390/ph14080707
15. Bhange, M., Telange, D.: Convergence of nanotechnology and artificial intelligence in the fight against liver cancer: a comprehensive review. Discov. Oncol. 16, 77 (2025). https://doi.org/10.1007/s12672-025-01821-y
16. Alum, E.U., Nwuruku, O.A., Ugwu, O.P.-C., Uti, D.E., Alum, B.N., Edwin, N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomedicine Plus. 5, 100828 (2025). https://doi.org/10.1016/j.phyplu.2025.100828
17. Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., Alcudia, A.: Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. Nanomaterials. 10, 1403 (2020). https://doi.org/10.3390/nano10071403
18. kapoor, D. u, Garg, R., Gaur, M., Prajapati, B.G., Agrawal, G., Bhattacharya, S., Elossaily, G.M.: Polymeric nanoparticles approach and identification and characterization of novel biomarkers for colon cancer. Results Chem. 6, 101167 (2023). https://doi.org/10.1016/j.rechem.2023.101167
19. Zhang, W., Mehta, A., Tong, Z., Esser, L., Voelcker, N.H.: Development of Polymeric Nanoparticles for Blood–Brain Barrier Transfer—Strategies and Challenges. Adv. Sci. 8, 2003937 (2021). https://doi.org/10.1002/advs.202003937
20. Gulati, S., Yadav, R., Kumari, V., Nair, S., Gupta, C., Aishwari, M.: Nanosensors in healthcare: transforming real-time monitoring and disease management with cutting-edge nanotechnology. RSC Pharm. 2, 1003–1018 (2025). https://doi.org/10.1039/D5PM00125K
21. Mohanan, N.K., Mohanan, N.S., Sukumaran, S.M., Dhanya, T.M., Pillai, S.S., Rajan, P.K., Pillai, S.S.: An Insight into the Disease Prognostic Potentials of Nanosensors. Inorganics. 13, 259 (2025). https://doi.org/10.3390/inorganics13080259
22. Calatayud, D.G., Neophytou, S., Nicodemou, E., Giuffrida, S.G., Ge, H., Pascu, S.I.: Nano-Theranostics for the Sensing, Imaging and Therapy of Prostate Cancers. Front. Chem. 10, (2022). https://doi.org/10.3389/fchem.2022.830133
23. Gawne, P.J., Ferreira, M., Papaluca, M., Grimm, J., Decuzzi, P.: New Opportunities and Old Challenges in the Clinical translation of Nanotheranostics. Nat. Rev. Mater. 8, 783–798 (2023). https://doi.org/10.1038/s41578-023-00581-x
24. Hao, B., Wei, L., Cheng, Y., Ma, Z., Wang, J.: Advanced nanomaterial for prostate cancer theranostics. Front. Bioeng. Biotechnol. 10, 1046234 (2022). https://doi.org/10.3389/fbioe.2022.1046234
25. Kashyap, B.K., Singh, V.V., Solanki, M.K., Kumar, A., Ruokolainen, J., Kesari, K.K.: Smart Nanomaterials in Cancer Theranostics: Challenges and Opportunities. ACS Omega. 8, 14290–14320 (2023). https://doi.org/10.1021/acsomega.2c07840
26. Ghandforoushan, P., Hanaee, J., Aghazadeh, Z., Samiei, M., Navali, A.M., Khatibi, A., Davaran, S.: Enhancing the function of PLGA-collagen scaffold by incorporating TGF-β1-loaded PLGA-PEG-PLGA nanoparticles for cartilage tissue engineering using human dental pulp stem cells. Drug Deliv. Transl. Res. 12, 2960–2978 (2022). https://doi.org/10.1007/s13346-022-01161-2
27. Omidian, H., Wilson, R.L., Castejon, A.M.: Recent Advances in Peptide-Loaded PLGA Nanocarriers for Drug Delivery and Regenerative Medicine. Pharmaceuticals. 18, 127 (2025). https://doi.org/10.3390/ph18010127
28. Sharmah, B., Borthakur, A., Manna, P.: PLGA-Based Drug Delivery Systems: A Promising Carrier for Antidiabetic Drug Delivery. Adv. Ther. 7, 2300424 (2024). https://doi.org/10.1002/adtp.202300424
29. Long, Q., Liu, Z., Shao, Q., Shi, H., Huang, S., Jiang, C., Qian, B., Zhong, Y., He, X., Xiang, X., Yang, Y., Li, B., Yan, X., Zhao, Q., Wei, X., Santos, H.A., Ye, X.: Autologous Skin Fibroblast-Based PLGA Nanoparticles for Treating Multiorgan Fibrosis. Adv. Sci. 9, 2200856 (2022). https://doi.org/10.1002/advs.202200856
30. Abbasi, H., Kouchak, M., Mirveis, Z., Hajipour, F., Khodarahmi, M., Rahbar, N., Handali, S.: What We Need to Know about Liposomes as Drug Nanocarriers: An Updated Review. Adv. Pharm. Bull. 13, 7–23 (2023). https://doi.org/10.34172/apb.2023.009
31. García-Morales, J., Fimbres-Olivarría, D., González-Vega, R.I., Bernal-Mercado, A.T., Aubourg-Martínez, S.P., López-Gastélum, K.A., Robles-García, M.Á., de Jesús Ornelas-Paz, J., Ruiz-Cruz, S., Del-Toro-Sánchez, C.L.: Nanoliposomes as Effective Vehicles of Antioxidant Compounds in Food and Health. Int. J. Mol. Sci. 26, 5523 (2025). https://doi.org/10.3390/ijms26125523

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

32. Wang, S., Chen, Y., Guo, J., Huang, Q.: Liposomes for Tumor Targeted Therapy: A Review. Int. J. Mol. Sci. 24, 2643 (2023). https://doi.org/10.3390/ijms24032643
33. Xue, L., Wang, D., Zhang, X., Xu, S., Zhang, N.: Targeted and triple therapy-based liposomes for enhanced treatment of rheumatoid arthritis. Int. J. Pharm. 586, 119642 (2020). https://doi.org/10.1016/j.ijpharm.2020.119642
34. Wang, W., Zhou, M., Xu, Y., Peng, W., Zhang, S., Li, R., Zhang, H., Zhang, H., Cheng, S., Wang, Y., Wei, X., Yue, C., Yang, Q., Chen, C.: Resveratrol-Loaded TPGS-Resveratrol-Solid Lipid Nanoparticles for Multidrug-Resistant Therapy of Breast Cancer: In Vivo and In Vitro Study. Front. Bioeng. Biotechnol. 9, 762489 (2021). https://doi.org/10.3389/fbioe.2021.762489
35. Zeng, J., Tang, X., Qin, D., Yu, L., Zhou, X., Feng, C., Mi, J., Pan, H., Wu, J., Huang, B., Wu, A.: Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases. J. Nanobiotechnology. 23, 682 (2025). https://doi.org/10.1186/s12951-025-03677-4
36. Sibuyi, N.R.S., Moabelo, K.L., Meyer, M., Onani, M.O., Dube, A., Madiehe, A.M.: Nanotechnology advances towards development of targeted-treatment for obesity. J. Nanobiotechnology. 17, 122 (2019). https://doi.org/10.1186/s12951-019-0554-3
37. Jaiswal, M., Dudhe, R., Sharma, P.K.: Nanoemulsion: an advanced mode of drug delivery system. 3 Biotech. 5, 123–127 (2015). https://doi.org/10.1007/s13205-014-0214-0
38. Chang, W., Meng, Z., Zhao, Y., Qi, Y., Li, Z., Lian, H.: Emerging Nanotechnology Strategies for Obesity Therapy. Adv. Sci. 12, e01813 (2025). https://doi.org/10.1002/advs.202501813
39. Dong, Y., Eltoukhy, A.A., Alabi, C.A., Khan, O.F., Veiseh, O., Dorkin, J.R., Sirirungruang, S., Yin, H., Tang, B.C., Pelet, J.M., Chen, D., Gu, Z., Xue, Y., Langer, R., Anderson, D.G.: Lipid-like Nanomaterials for simultaneous gene expression and silencing in vivo. Adv. Healthc. Mater. 3, 1392–1397 (2014). https://doi.org/10.1002/adhm.201400054
40. Alum, E.U.: Optimizing patient education for sustainable self-management in type 2 diabetes. Discov. Public Health. 22, 44 (2025). https://doi.org/10.1186/s12982-025-00445-5
41. Cappon, G., Vettoretti, M., Sparacino, G., Facchinetti, A.: Continuous Glucose Monitoring Sensors for Diabetes Management: A Review of Technologies and Applications. Diabetes Metab. J. 43, 383–397 (2019). https://doi.org/10.4093/dmj.2019.0121
42. Debnath, S., Debnath, T., Paul, M.: A Review of Graphene-Integrated Biosensors for Non-Invasive Biochemical Monitoring in Health Applications. Sensors. 25, 6553 (2025). https://doi.org/10.3390/s25216553
43. Hai, X., Zhu, X., Yu, K., Yue, S., Song, W., Bi, S.: Dual-mode glucose nanosensor as an activatable theranostic platform for cancer cell recognition and cascades-enhanced synergetic therapy. Biosens. Bioelectron. 192, 113544 (2021). https://doi.org/10.1016/j.bios.2021.113544
44. Zheng, Y., Luo, S., Xu, M., He, Q., Xie, J., Wu, J., Huang, Y.: Transepithelial transport of nanoparticles in oral drug delivery: From the perspective of surface and holistic property modulation. Acta Pharm. Sin. B. 14, 3876–3900 (2024). https://doi.org/10.1016/j.apsb.2024.06.015
45. Ma, J., Li, X., Wang, C.: The Application of Nanomaterials in the Treatment of Pancreatic-Related Diseases. Int. J. Mol. Sci. 25, 13158 (2024). https://doi.org/10.3390/ijms252313158
46. Sheikh, A., Kesharwani, P., Almalki, W.H., Almujri, S.S., Dai, L., Chen, Z.-S., Sahebkar, A., Gao, F.: Understanding the Novel Approach of Nanoferroptosis for Cancer Therapy. Nano-Micro Lett. 16, 188 (2024). https://doi.org/10.1007/s40820-024-01399-0
47. Manke, A., Wang, L., Rojanasakul, Y.: Mechanisms of Nanoparticle-Induced Oxidative Stress and Toxicity. BioMed Res. Int. 2013, 942916 (2013). https://doi.org/10.1155/2013/942916
48. Khorasani, M.A., Naghib, S.M., Jafari, T., Takdehghan, G.: Recent advances in engineering chitosan-based nanoplatforms in biotherapeutic multi-delivery for multi-targeted disease treatments: Promises and outlooks. Colloid Interface Sci. Commun. 69, 100861 (2025). https://doi.org/10.1016/j.colcom.2025.100861
49. Souto, E.B., Blanco-Llamero, C., Krambeck, K., Kiran, N.S., Yashaswini, C., Postwala, H., Severino, P., Priefer, R., Prajapati, B.G., Maheshwari, R.: Regulatory insights into nanomedicine and gene vaccine innovation: Safety assessment, challenges, and regulatory perspectives. Acta Biomater. 180, 1–17 (2024). https://doi.org/10.1016/j.actbio.2024.04.010

CITE AS: Maina Mwaura F. (2026). Nanotechnology in the Management of Obesity and Diabetes: A Convergent Frontier in Metabolic Disease Therapy. NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES. https://doi.org/10.59298/NIJRMS/2026/7.1.8186